July 2022 - Volume 81 - 7

Recommendation

1. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist

Heroes and pillars of rheumatology

2. Eleonora Reicher: a pioneer of European rheumatology

Rheumatoid arthritis

3. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

4. Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis

Psoriatic arthritis

5. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

Systemic lupus erythematosus

6. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

7. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

8. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Sjögren’s syndrome

9. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome

Paediatric rheumatology

10. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial

11. Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases

Autoimmunity

12. Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity

Epidemiology

13. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases

14. Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study

15. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease

16. BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study

17. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases

Letters

18. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19

19. Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine

20. Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis

21. Pilot study of baricitinib for active Sjogren’s syndrome

22. Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations

Electronic pages

23. High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern

24. Response to: ‘High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern?’ by Inanc et al

25. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study

26. Response to: ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study’ by Goulielmos and Zervou

27. Microbiome in Sjögren’s syndrome: here we are

28. Response to: ‘Microbiome in Sjögren’s syndrome: here we are’ by van der Meulen et al

29. Riociguat in systemic sclerosis: a potential for disease modification

30. Response to: ‘Riociguat in systemic sclerosis: a potential for disease modification’ by Jain and Dhir

31. ‘Halo Score’: missing large-vessel giant cell arteritis— do we need a ‘modified Halo Score’?

32. Response to: ‘‘Halo Score’: missing large vessel giant cell arteritis– do we need a modified ‘Halo Score?’’ by Chattopadhyay and Ghosh

33. Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease

34. Response to: ‘Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease’ by Akiyama et al

35. Confounding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’

36. Response to: ‘Confunding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’’ by Hsu et al

37. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

38. Response to: ‘Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland’ by Quills et al

39. Changes in synovitis and bone marrow lesions may not mediate the effect of cartilage loss on joint pain in osteoarthritis

40. Relation between cartilage loss and pain in knee osteoarthritis

41. Response to: ‘Relation between cartilage loss and pain in knee osteoarthritis’ by Wu et al and ‘Changes in synovitis and bone marrow lesions may not mediate the effect of cartilage loss on joint pain in osteoarthritis’ by Cashin et al

42. Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease

43. Response to: ‘Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease’ by Alunno et al

44. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors

45. Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al

46. Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

PDF

Issue Information